Cyclothymic Disorder: Symptoms, Diagnosis, and Long-Term Course
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Cyclothymic disorder, commonly called cyclothymia, is a recognized bipolar-related mood disorder defined by a long-standing pattern of recurrent elevated and depressive symptoms. The changes are clinically meaningful, yet the symptom periods do not meet the full diagnostic threshold for the mood episodes required in bipolar I or bipolar II disorder under DSM-5-TR criteria. The defining problem is the persistence and fluctuation of the pattern across years, often affecting relationships, judgment, sleep, consistency at work or school, and everyday well-being. National Institute of Mental Health and Merck Manual Professional Edition explain this diagnostic distinction.
The word cyclothymia is sometimes used casually to describe an emotionally changeable personality. A clinical diagnosis requires a specific longitudinal history, a sustained burden of symptoms, functional consequences, and assessment of other explanations. Frequent mood changes alone do not establish cyclothymic disorder. This guide explains the clinical definition, what the changes feel like, how assessment works, the evidence about long-term outcomes, and what treatment can reasonably achieve.
For additional clinical context, see Types of Bipolar Disorder: Bipolar I, Bipolar II, Cyclothymia, and Other Forms, Bipolar II Disorder: Symptoms, Diagnosis, and Treatment and Other Specified Bipolar and Related Disorder: What the Diagnosis Means.
What is cyclothymic disorder?
Cyclothymic disorder belongs to the bipolar and related disorders family. It involves numerous periods of hypomanic symptoms—such as a noticeable increase in energy, activity, talkativeness, confidence, or reduced need for sleep—and numerous periods of depressive symptoms, such as diminished interest, low energy, reduced motivation, sadness, or impaired concentration. These experiences recur over an extended period and have a recognizable course. In the DSM-5-TR framework, neither set of symptoms reaches the criteria for a full hypomanic episode or a major depressive episode. Merck Manual gives the formal clinical outline.
The distinction between symptoms and a full episode matters. A symptom can be genuine and disruptive without reaching the required intensity, duration, number of associated symptoms, or impairment threshold of a specific mood episode. Cyclothymia can therefore cause substantial accumulated disruption despite containing periods that appear less severe when examined separately. A person may seek care because of exhaustion, conflict, inconsistent functioning, depression, or anxiety rather than recognizing the recurring elevated states. Mayo Clinic describes the range of presentations and resulting difficulties.
Cyclothymia symptoms: the elevated and low periods
Elevated or hypomanic symptoms
During an elevated period, someone may speak more quickly, generate many plans, pursue goals intensely, feel unusually upbeat or irritable, become more sociable, shift rapidly between projects, or act with less deliberation. Sleep may become shorter without the expected fatigue. Such changes are assessed relative to that person's usual behavior and in context: a naturally energetic temperament, enthusiasm for a new project, and a temporary response to good news do not by themselves indicate illness. The clinical question is whether recurrent shifts are distinct, persistent, and consequential. NIMH describes relevant changes in mood, energy, sleep, speech, activity, and decision-making across bipolar-related conditions.
Some elevated stretches feel productive, pleasurable, and entirely reasonable to the person experiencing them. Other people may first notice increased irritability, impulsive commitments, excessive confidence, escalating disagreements, or financial decisions that later require repair. A cyclothymic elevated period remains below the DSM threshold for a full hypomanic episode. If a true manic episode emerges, particularly with severe impairment, hospitalization, or psychosis, the clinician reassesses the diagnosis rather than treating it as routine cyclothymia. Merck Manual and NIMH provide the diagnostic boundary.
Depressive symptoms
Low periods may involve persistent sadness or emptiness, loss of interest, low energy, fatigue, pessimism, feelings of inadequacy, withdrawal, altered sleep, difficulty concentrating, or reduced motivation. Such symptoms may seriously affect family and work life without reaching the complete diagnostic requirements for a major depressive episode. The repeated return of symptoms and their interaction with preceding periods of increased activity can be particularly disruptive. Mayo Clinic describes the depressive presentation of cyclothymia.
Depressive periods also warrant an assessment of suicidal thoughts, hopelessness, substance use, and functional decline. Symptom severity and safety require clinical attention even when a person does not meet the formal threshold for major depression. If a full major depressive episode is identified, clinicians reconsider the longitudinal classification and determine which mood-disorder diagnosis best fits the entire history. NIMH outlines the importance of depressive symptoms and safety across bipolar-related illness.
What happens between the highs and lows?
Cyclothymia does not require abrupt switches or a predictable cycle. Symptom-free stretches can occur, and one polarity can be more noticeable than the other. Some people experience changes over days or weeks, while others describe a complex background pattern of recurrent symptoms; the diagnostic time requirement concerns the aggregate longitudinal course, not a fixed number of hours per mood shift. This is why a brief office visit rarely captures the relevant story. Mayo Clinic's diagnostic guidance recommends mood charting and collateral history where appropriate.
Diagnostic criteria: how long must symptoms last?
Under the DSM-5-TR approach used in much U.S. clinical practice, cyclothymic disorder requires numerous periods with hypomanic symptoms and numerous periods with depressive symptoms lasting at least two years in adults, or at least one year in children and adolescents. During that period the symptoms must be present at least half the time, with no interval entirely free of both sets of symptoms lasting longer than two months. The symptoms must cause clinically significant distress or impairment and cannot be better explained by substances, medication effects, another medical condition, or a different psychiatric disorder. Merck Manual's DSM-5-TR summary and Mayo Clinic set out these requirements.
The episode-threshold rule is central. DSM-5-TR cyclothymic disorder is defined by a history in which the criteria for a major depressive, manic, or hypomanic episode have not been met. A confirmed past episode can change the diagnostic classification. A clinician also evaluates whether symptoms have been present for long enough, whether they represent a departure from baseline, and whether another condition explains the changes better. The two-year rule is a minimum qualifying history for an adult diagnosis, not an instruction to postpone professional assessment for two years. Merck Manual summarizes the diagnostic requirements.
DSM-5-TR and ICD-11: why the diagnostic system matters
DSM-5-TR and the World Health Organization's ICD-11 both recognize cyclothymic disorder, but their descriptions are not completely identical. In particular, published comparisons indicate that ICD-11 allows some hypomanic periods that reach an episode threshold while emphasizing that depressive periods do not meet the requirements for a full depressive episode; DSM-5-TR uses a stricter symptom-below-episode-threshold definition. A psychiatrist should specify the diagnostic system being applied and interpret the whole history accordingly. Chakrabarti's comparative review of ICD-11 and DSM criteria discusses these differences and their uncertainties.
Cyclothymia vs bipolar I, bipolar II, and ordinary mood swings
Bipolar I disorder is diagnosed on the basis of at least one manic episode; the episode can involve marked impairment, hospitalization, or psychotic symptoms. Bipolar II disorder involves the required combination of a hypomanic episode and a major depressive episode, without a history of mania. Cyclothymia describes a chronic recurrent symptom pattern that falls below the DSM episode thresholds. Bipolar II is not simply a milder version of bipolar I: major depressive episodes can be severe and disabling. NIMH explains the principal distinctions.
Ordinary changes in mood can accompany sleep loss, stress, relationships, hormonal fluctuations, illness, and rewarding events. They become clinically relevant when their quality, duration, recurrence, and impact support a recognizable syndrome. Severe emotional reactivity, alternating feelings within a day, or identifying as a 'moody person' are insufficient to diagnose cyclothymia. The clinician looks for the full history of both elevated and depressive symptoms rather than treating any fast-changing emotion as a bipolar-spectrum episode. Mayo Clinic's diagnostic guidance emphasizes careful differential assessment.
Other specified bipolar and related disorder is another distinct category. It may be considered when clinically important bipolar-like symptoms fail to meet criteria for a more specific diagnosis but have a definable presentation. It is not a synonym for cyclothymia, and the two labels should not be exchanged because a person's symptoms seem 'mild.' NIMH identifies other specified and unspecified bipolar-related diagnoses as separate categories.
How clinicians diagnose cyclothymic disorder
The clinical interview and timeline
Assessment generally starts by reconstructing years of mood, energy, activity, sleep, motivation, decisions, and functioning. A clinician asks when symptoms began, how long they persisted, how often both polarities returned, whether sustained symptom-free intervals occurred, and whether a full mood episode ever took place. Medical records, prior assessments, medication histories, and—with permission—observations from trusted people can help, particularly when elevated periods felt normal or desirable. Mayo Clinic describes clinical interview, psychological evaluation, and mood tracking; NICE's bipolar assessment guidance supports a detailed longitudinal history and consideration of collateral information.
An assessment also considers depression severity, suicidal thoughts, psychotic experiences, agitation, sleep disruption, financial or sexual risk taking, substance use, relationship impacts, anxiety, and co-occurring developmental or personality characteristics. The clinician may use questionnaires to structure the conversation, but a score on the Mood Disorder Questionnaire or another bipolar screener cannot distinguish cyclothymia reliably from every competing explanation. Screening establishes a reason to assess; diagnosis depends on clinical interpretation of history and functional consequences. VA/DoD's 2023 assessment and triage guideline covers bipolar-related clinical assessment.
Medical and medication review
Thyroid disease and other medical conditions, stimulant exposure, corticosteroids, antidepressants, recreational substances, and disrupted sleep can produce mood or activity changes that resemble aspects of a bipolar-related presentation. The evaluation includes relevant current and past medications, alcohol and drug use, physical symptoms, and selectively chosen medical tests. A blood test does not establish cyclothymic disorder; tests are used to investigate possible contributing or alternative medical causes. Mayo Clinic describes the role of examination and laboratory investigation.
When a mood diary helps
A daily record may capture mood, energy, sleep duration, perceived need for sleep, stressors, substance use, major events, and day-to-day impairment. Its value lies in revealing patterns over weeks and months and making conversations with the clinician more precise. The diary remains a record of observations, not a diagnostic instrument with an automatic cutoff. Recording extreme mood labels without context can obscure more than it clarifies; changes in baseline functioning, sleep, and consequences are often more informative. Mayo Clinic recommends mood charting as part of assessment and care.
Conditions that can resemble or coexist with cyclothymia
Recurrent unipolar depression can explain repeated low periods, but a history of distinct elevated symptoms changes the differential diagnosis. Persistent depressive disorder involves a different chronic depressive pattern. ADHD can cause long-standing activity, impulsivity, and concentration difficulties; clinicians look for persistent developmental traits versus episodic changes in mood and energy. Borderline personality disorder can involve strong emotional reactivity and relationship-linked distress, while bipolar-related evaluation asks about the full longitudinal course of elevated and depressive states. These patterns may overlap or coexist, and single symptoms cannot settle the question. NICE advises assessing coexisting disorders in bipolar care, and Merck Manual addresses diagnostic differentiation.
Anxiety disorders, trauma-related symptoms, substance use, sleep-wake disorders, and ordinary temperament variations can also shape a presentation. The assessment should remain broad enough to identify treatable problems whether or not cyclothymia ultimately fits. Likewise, a full manic episode, psychosis, or an episode of major depression requires its own careful assessment and possible reclassification. The practical result is a formulation that explains the individual history and directs care, rather than a label assigned after a quick symptom checklist. Mayo Clinic and VA/DoD support comprehensive evaluation.
What causes cyclothymia? Genetics, temperament, and environmental factors
The cause of cyclothymic disorder is not established as a single biological mechanism. Family aggregation of bipolar-related and depressive disorders suggests shared susceptibility; sleep, stress exposure, individual temperament, and environmental context may affect how symptoms emerge and recur. Research on bipolar disorders more broadly informs these hypotheses, but mechanisms demonstrated in bipolar I samples cannot automatically be treated as independently proven for cyclothymia. Mayo Clinic's overview of causes and Perugi and colleagues' review discuss the multifactorial picture.
Cyclothymic temperament is a research and clinical concept describing a tendency toward mood variability. It is related to, but not interchangeable with, the diagnosis of cyclothymic disorder. Research describing temperament and emotional reactivity may clarify vulnerability without proving that every person with a changeable temperament has a disorder. The diagnosis still depends on longitudinal symptoms, clinically meaningful impairment, and exclusion of better explanations. The proposal to understand cyclothymia primarily as an intensified temperament is one perspective in the literature, rather than a replacement for established DSM-5-TR criteria. Perugi, Hantouche, and Vannucchi (2017) articulate that perspective.
How common is cyclothymia, and when does it begin?
Cyclothymia often begins in adolescence or early adulthood, although the onset can be recognized retrospectively after years of symptoms. Prevalence estimates depend on the diagnostic instrument, population, age range, and criteria used. A community survey in Florence reported a point prevalence of 0.4% for cyclothymia; this is one study in a specific setting and should not be generalized as a current global figure. Research that groups different subthreshold bipolar presentations together makes cyclothymia-specific prevalence and burden difficult to measure precisely. Faravelli and colleagues' community survey and Van Meter and Youngstrom's review illustrate these methodological constraints.
In young people, differentiating persistent mood instability from developmental changes, chronic irritability, ADHD, sleep disruption, and other conditions is particularly difficult. A child may show changes primarily through irritability rather than an overtly elevated mood. Childhood and adolescent diagnoses require a developmental interview and careful longitudinal evaluation; adult studies should not be applied wholesale to pediatric populations. Van Meter and Youngstrom (2012) review these challenges and the limited youth-specific evidence.
Long-term course: can cyclothymia go away or develop into bipolar I or II?
Cyclothymia often has a prolonged and fluctuating course. Symptoms may improve substantially with appropriate care, become less disruptive, persist over years, or later meet criteria for a different mood-disorder diagnosis. A chronic diagnostic description does not imply continuous daily distress, fixed severity, or an inevitable worsening trajectory. What matters most for prognosis is a person's observed longitudinal pattern, coexisting problems, ability to obtain effective care, and emerging changes in the severity of mood symptoms. Mayo Clinic describes the long-term management rationale; Van Meter and Youngstrom summarize longitudinal questions.
Some people who initially meet criteria for cyclothymia later experience full hypomanic, manic, or major depressive episodes and receive a revised diagnosis. A prospective study followed a selected nonclinical group of young adults with early-onset bipolar-spectrum symptoms. Among 57 participants initially classified as either cyclothymia or bipolar disorder not otherwise specified, 42.1% developed bipolar II and 10.5% developed bipolar I diagnoses over an average 4.5-year follow-up. These percentages describe a small combined, selected research group; they are not the lifetime risk for every person with cyclothymic disorder. Alloy and colleagues' prospective study provides the actual population, denominators, and limitations.
That research also examined characteristics associated with diagnostic progression, including early onset and certain dimensions of impulsivity and reward sensitivity. Associations within a selected cohort are not individually predictive tests. A clinician cannot infer a person's future diagnosis from a personality trait, family history alone, or an online risk calculator. Long-term follow-up is valuable because it detects clinically significant change and allows treatment plans to be reconsidered when new evidence emerges. Alloy and colleagues report the findings.
What does recovery mean for a chronic mood pattern?
Recovery can include fewer disruptive fluctuations, more reliable sleep, improved interpersonal functioning, steadier work or school participation, and greater ability to recognize early warning signs. Some people experience extended improvement or symptom remission. Others benefit from continuing care as symptoms return. The aim is meaningful functioning and safety in the person's actual circumstances, not an arbitrary promise of permanent symptom elimination. Care plans should be revisited over time and adjusted to clinical need. Mayo Clinic describes long-term management and relapse prevention.
Evidence-based treatment: what can help?
The evidence base for cyclothymic disorder is considerably smaller than the evidence base for bipolar I or bipolar II. This limits confidence in specific treatment rankings. A systematic review or drug trial performed predominantly in bipolar I patients cannot establish that the same intervention has equal benefit for cyclothymia. Current care commonly combines individualized assessment, psychoeducation, psychotherapy, attention to daily routines, management of coexisting conditions, and, when appropriate, clinician-supervised medication. Van Meter and Youngstrom discuss the sparse direct evidence; VA/DoD and CANMAT/ISBD's 2023 evidence update provide broader bipolar-specific guidance that requires diagnosis-appropriate interpretation.
Psychotherapy and psychoeducation
Psychotherapy can address the consequences of recurring mood changes, improve recognition of patterns, establish practical coping strategies, and support work, sleep, relationships, and treatment decisions. Cognitive behavioral approaches may help with habitual thoughts, behavioral responses, and stress management. Interpersonal and social rhythm approaches focus on consistent schedules and interpersonal pressures. Family-focused work can help relatives recognize changes and communicate without attributing every conflict to illness. These approaches are clinically plausible and used in practice; direct comparative trials in clearly diagnosed cyclothymia remain limited. Mayo Clinic describes psychotherapy options.
A 2021 systematic review and component network meta-analysis included 39 randomized trials of adjunctive psychotherapy for bipolar disorder and found evidence that structured family, cognitive behavioral, and psychoeducational interventions could reduce recurrence when added to usual pharmacological care. Its principal estimates concern studied bipolar populations, not a proven cyclothymia-specific effect. It supports further attention to psychosocial management without justifying a guarantee that a particular therapy prevents progression from cyclothymia to bipolar I or II. Miklowitz and colleagues (2021) provide the methods and results.
Medications: possible roles and limitations
There is no U.S. Food and Drug Administration-approved medication specifically indicated for cyclothymic disorder. If symptoms are persistent, impairing, or accompanied by significant risk, a psychiatrist may consider a medication used in bipolar care after discussing the expected benefit, uncertain cyclothymia-specific evidence, adverse effects, relevant medical history, pregnancy considerations, and monitoring. Options sometimes considered include lithium, lamotrigine, or other mood-stabilizing treatments; their roles differ by clinical presentation and evidence. Drug choice cannot be safely inferred from this article. Mayo Clinic states the cyclothymia-specific approval limitation; CANMAT/ISBD summarizes phase-specific bipolar pharmacotherapy.
Lithium requires individualized monitoring of blood levels, kidney function, thyroid function, and interacting medicines. Lamotrigine requires careful dose titration because of the risk of serious skin reactions; promptly report a new rash or other concerning symptoms according to medical advice. Valproate carries major reproductive and fetal risks, alongside hepatic and hematologic monitoring considerations. Antipsychotic medicines may have metabolic, movement-related, and other adverse effects. The appropriateness of these medications for cyclothymia is a separate clinical judgment from their efficacy in other bipolar diagnoses. NICE's medication and monitoring recommendations provide relevant safety requirements.
Antidepressants deserve particular scrutiny in a person with possible bipolar-spectrum symptoms because activation, mood switching, or worsening instability may occur in some patients. Such risks are neither universal nor proof that antidepressants can never be used; the decision depends on the actual diagnosis, depressive severity, prior response, other treatments, and specialist monitoring. A person already taking a prescription should not stop, start, or change the dose independently after reading about cyclothymia. Merck Manual discusses caution with antidepressants and NICE addresses medication management.
What an individualized care plan covers
A clinically useful plan identifies the person's most disruptive symptoms, goals, acute safety risks, typical early warning signs, effects on sleep and functioning, possible substance contributions, needed medical assessment, and who will coordinate care. It should specify what requires routine follow-up and what warrants faster reassessment. Response is monitored over time, including medication adverse effects when medication is used. The plan changes when a full mood episode, a new comorbid condition, or substantially altered circumstances emerge. VA/DoD's clinical framework emphasizes assessment, triage, specialized care, and phase-appropriate management.
Living with cyclothymia: practical self-management and support
Regular sleep and wake times, manageable daily routines, consistent meals, physical activity adapted to health, and attention to stress can make mood patterns easier to recognize and support overall health. Avoiding alcohol and recreational drugs that worsen mood instability or disrupt treatment can also be important. These measures complement evaluation and treatment; they cannot establish a diagnosis or replace care when symptoms cause harm. Mayo Clinic's treatment guidance includes routine stabilization and ongoing follow-up.
A practical approach to mood tracking uses a few consistent daily observations rather than a complicated scoring system. Record sleep, energy, mood, significant decisions, medication changes if relevant, and consequences at school, work, or home. Review the pattern with a clinician instead of treating every recorded change as a disorder episode. Close relatives can help by describing what they notice factually and supporting appointments when invited, while respecting autonomy and privacy. Mayo Clinic explains how tracking and collaborative assessment can contribute.
For relationships, the most useful conversation concerns observable events and agreements: how to handle impulsive commitments, how to discuss periods of withdrawal, what warning signs both parties recognize, and which circumstances call for outside help. A diagnostic label does not automatically explain every disagreement. Support is strongest when it remains specific, consent-based, and compatible with the person's own goals. Broader bipolar psychoeducation research supports attention to shared skills and communication, although cyclothymia-specific trials are still sparse. Miklowitz and colleagues provide the wider evidence context.
Safety: when to seek urgent assessment
A change from the usual pattern toward severely reduced need for sleep, escalating impulsivity, dangerous decisions, marked agitation, loss of touch with reality, or profound depression warrants prompt clinical evaluation. Psychosis, an apparent manic episode, inability to care for basic needs, or immediate risk of harm requires urgent assessment because the diagnostic picture and immediate priorities may have changed. Do not assume a previous cyclothymia label adequately explains new severe symptoms. NIMH and VA/DoD describe the seriousness of severe bipolar-related episodes.
If someone is considering suicide, has a plan or intent to act, or cannot stay safe, contact local emergency services or an emergency department immediately. In the United States, call or text 988 to reach the Suicide & Crisis Lifeline for crisis support; for immediate danger, call 911. Elsewhere, use local emergency and crisis services. When supporting another person, stay with them if it is safe to do so and help connect them to urgent professional care. Mayo Clinic's cyclothymia safety guidance addresses urgent help for suicidal thinking.
Common misunderstandings about cyclothymic disorder
Cyclothymia does not mean being happy one hour and sad the next. The clinical concept concerns a recurrent symptom pattern over a defined minimum period with meaningful consequences. It is also inaccurate to describe cyclothymia as a harmless personality quirk: long-term instability can cause substantial distress, although the absence of a full manic or depressive episode is diagnostically important. Merck Manual explains the diagnostic pattern.
Cyclothymia is not identical to bipolar II, and it is not necessarily an early stage that inevitably progresses to bipolar I. Progression is possible, but individual outcomes vary and the available rates depend heavily on study design and participant selection. A normal period of feeling well does not invalidate a prior chronic mood history, and no single mood diary or screening tool can establish the diagnosis. Alloy and colleagues and Mayo Clinic support those distinctions.
Frequently asked questions
Is cyclothymia a type of bipolar disorder?
It is classified among bipolar and related disorders in major diagnostic frameworks. Under DSM-5-TR, cyclothymia has its own criteria centered on prolonged hypomanic and depressive symptoms below the full episode thresholds. It should be identified by those criteria rather than used as a general label for moodiness. NIMH describes its place in the classification.
How do I know whether I have cyclothymia?
A mental health professional needs to examine the history of both elevated and depressive symptoms over time, the length of symptom-free periods, distress or impairment, medical and substance factors, and possible full mood episodes. Self-observation and symptom questionnaires may help prepare for that conversation, but they cannot establish cyclothymia. Mayo Clinic outlines the diagnostic process.
Can cyclothymia be diagnosed before two years?
A clinician can evaluate and treat concerning symptoms immediately. For the DSM-5-TR adult cyclothymic disorder diagnosis, the qualifying history must span at least two years; the duration requirement is one year for children and adolescents. Other diagnoses or a provisional clinical formulation may be more appropriate before that history is established. Merck Manual states these duration requirements.
Can cyclothymia develop into bipolar II disorder?
Yes, some people later meet the criteria for bipolar II or bipolar I disorder. The probability for any individual cannot be read directly from small combined research cohorts or a generic web statistic. New full mood episodes should trigger reassessment and a corresponding review of treatment. Alloy and colleagues' longitudinal study documents progression in one selected population.
Is cyclothymia curable?
Cyclothymia can improve, sometimes considerably, and a person's goals may include sustained symptom relief and functional recovery. Its potential chronicity makes follow-up valuable, while prognosis differs between individuals. Treatment studies have not established a universal permanent cure or a fixed recovery timetable. Mayo Clinic discusses ongoing care and symptom management.
Is there a definitive cyclothymia test?
No blood test, brain scan, or online questionnaire independently confirms the diagnosis. Clinical assessment may use medical tests to investigate alternatives and mood records to clarify course, but the diagnosis remains based on the interpreted history and diagnostic criteria. Mayo Clinic describes the appropriate role of these tools.
Can children or teenagers have cyclothymia?
The diagnostic framework allows it, with a one-year symptom duration criterion in young people. Careful evaluation is especially important because irritability, emotional development, ADHD, stress, and sleep changes can complicate recognition. Evidence about the best cyclothymia-specific treatments in children is limited. Van Meter and Youngstrom review the pediatric evidence.
What if my symptoms have suddenly become much more severe?
Seek prompt professional reassessment, especially if the changes involve severe sleep loss, dangerous behavior, suicidal thinking, mania-like symptoms, or psychosis. A new full episode can change both the diagnosis and the urgency of care. Immediate danger calls for emergency services. NIMH outlines urgent bipolar-related symptoms.
Related Articles
OCD vs Bipolar Disorder: What Is the Difference? — a focused comparison of obsessions, repetitive behaviors, mood episodes, and insight.
Neuroticism and Bipolar Disorder: Associations, State Effects, and Limits — how trait neuroticism differs from clinical mood episodes and why association does not equal diagnosis.
References
Alloy, L. B., et al. (2012). Progression along the bipolar spectrum: A longitudinal study of predictors of conversion from bipolar spectrum conditions to bipolar I and II disorders. Journal of Abnormal Psychology, 121(1), 16–27. PubMed record.
Chakrabarti, S. (2022). Bipolar disorder in the International Classification of Diseases-Eleventh version: A review of the changes, their basis, and usefulness. World Journal of Psychiatry, 12(12), 1335–1355. DOI: 10.5498/wjp.v12.i12.1335.
Faravelli, C., Guerrini Degl'Innocenti, B., Aiazzi, L., Incerpi, G., & Pallanti, S. (1990). Epidemiology of mood disorders: A community survey in Florence. Journal of Affective Disorders, 20(2), 135–141. DOI: 10.1016/0165-0327(90)90127-T.
Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344–353. DOI: 10.1176/appi.focus.20230009.
Mayo Clinic. Cyclothymia (cyclothymic disorder): Diagnosis and treatment. Clinical reference.
Mayo Clinic. Cyclothymia (cyclothymic disorder): Symptoms and causes. Clinical reference.
Merck Manual Professional Edition. Cyclothymic disorder. Clinical reference.
Miklowitz, D. J., et al. (2021). Adjunctive psychotherapy for bipolar disorder: A systematic review and component network meta-analysis. JAMA Psychiatry, 78(2), 141–150. DOI: 10.1001/jamapsychiatry.2020.2993.
National Institute of Mental Health. Bipolar disorder. Official health publication.
National Institute for Health and Care Excellence. Bipolar disorder: Assessment and management. Clinical guideline CG185, updated September 2, 2025. Guideline.
Perugi, G., Hantouche, E., & Vannucchi, G. (2017). Diagnosis and treatment of cyclothymia: The primacy of temperament. Current Neuropharmacology, 15(3), 372–379. DOI: 10.2174/1570159X14666160616120157.
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for management of bipolar disorder. Official guideline.
Van Meter, A. R., & Youngstrom, E. A. (2012). Cyclothymic disorder in youth: Why is it overlooked, what do we know and where is the field headed? Neuropsychiatry, 2(6), 509–519. DOI: 10.2217/npy.12.64.